Search Result

Isoforms Recommended:	CDK7

Results for "

cdk7

" in MedChemExpress (MCE) Product Catalog:

By Targets:	CDK (102) AAK1 (1) Androgen Receptor (1) Apoptosis (21) Autophagy (2) Bcl-2 Family (1) c-Myc (6) Casein Kinase (2) DNA/RNA Synthesis (4) E3 Ligase Ligand-Linker Conjugates (1) Early 2 Factor (E2F) (2) Ephrin Receptor (1) ERK (1) FGFR (1) GSK-3 (1) HDAC (1) HIV (2) HSV (2) IRAK (1) Isotope-Labeled Compounds (1) Itk (1) JAK (1) Ligands for Target Protein for PROTAC (4) MAP4K (1) MDM-2/p53 (1) MELK (1) Molecular Glues (2) p38 MAPK (1) PKC (1) PROTACs (7) Reactive Oxygen Species (ROS) (1) Reference Standards (3) Ser/Thr Kinase (1) Small Interfering RNA (siRNA) (3) Target Protein Ligand-Linker Conjugates (1) Topoisomerase (2) ULK (1) Wee1 (1) Wnt (2) β-catenin (1)
By Research Areas:	Cancer (97) Cardiovascular Disease (1) Infection (3) Inflammation/Immunology (3) Metabolic Disease (4) Neurological Disease (3)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

104

Inhibitors & Agonists

Peptides

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Targets Recommended: CDK

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-138293

SY-5609 5+ Cited Publications cdk7-IN-3	CDK Apoptosis	Cancer
SY-5609 (CDK7-IN-3) is an orally active, highly selective, noncovalent *CDK7* inhibitor with a K_D of 0.065 nM. SY-5609 shows poor inhibition on CDK2 (K_i=2600 nM), CDK9 (K_i=960 nM), CDK12 (K_i=870 nM). SY-5609 induces apoptosis in tumor cells and has antitumor activity .

HY-10008

SNS-032 10+ Cited Publications BMS-387032	CDK Apoptosis	Cancer
SNS-032 (BMS-387032) is a potent and selective inhibitor of *CDK2, CDK7, and CDK9* with IC₅₀s of 38 nM, 62 nM and 4 nM, respectively. SNS-032 has antitumor effect .

HY-103712A

Samuraciclib hydrochloride 10+ Cited Publications CT7001 hydrochloride; ICEC0942 hydrochloride	CDK Apoptosis	Cancer
Samuraciclib hydrochloride (CT7001 hydrochloride) is a potent, selective, ATP-competitive and orally active *CDK7* inhibitor, with an IC₅₀ of 41 nM. Samuraciclib hydrochloride displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2 (IC₅₀ of 578 nM), CDK5 and CDK9, respectively. Samuraciclib hydrochloride inhibits the growth of breast cancer cell lines with GI₅₀ values between 0.2-0.3 µM. Samuraciclib hydrochloride has anti-tumor effects .

HY-101257

YKL-5-124 15+ Cited Publications	CDK	Cancer
YKL-5-124 is a potent, selective, irreversible and covalent *CDK7* inhibitor with IC₅₀s of 53.5 nM and 9.7 nM for *CDK7* and *CDK7/Mat1/CycH, respectively. YKL-5-124 is >100-fold greater selective for CDK7* than CDK9 and CDK2, and inactive against CDK12 and CDK13. YKL-5-124 induces a strong cell-cycle arrest, inhibits E2F-driven gene expression, and exhibits little effect on RNA polymerase II phosphorylation status .

HY-80013

THZ1 Maximum Cited Publications 93 Publications Verification	CDK	Cancer
THZ1 is a selective and potent covalent *CDK7* inhibitor with an IC₅₀ of 3.2 nM. THZ1 also inhibits the closely related kinases *CDK12* and *CDK13* and downregulates MYC expression .

HY-153278

Q901 cdk7-IN-21	CDK DNA/RNA Synthesis c-Myc Early 2 Factor (E2F) Topoisomerase	Cancer
Q901 (CDK7-IN-21) is a selective and potent *CDK7* inhibitor with an IC₅₀ of 10 nM. Q901 disrupts MYC and E2FTOP1-DPCs and sensitizes tumor to TOP1 inhibitors by suppressing RNAPII transition from initiation to elongation. Q901 can inhibit tumor growth and significantly enhances tumor growth inhibition combined with TOP1 inhibitors. Q901 can be used for the research of cancer, such as colon cancer and lung cancer .

HY-18340

(R)-CR8 1 Publications Verification CR8, (R)-Isomer	Molecular Glues CDK Apoptosis	Neurological Disease Cancer
(R)-CR8, a second-generation analog of Roscovitine, is a potent *CDK1/2/5/7/9* inhibitor. (R)-CR8 inhibits CDK1/cyclin B (IC₅₀=0.09 μM), CDK2/cyclin A (0.072 μM), CDK2/cyclin E (0.041 μM), CDK5/p25 (0.11 μM), CDK7/cyclin H (1.1 μM), CDK9/cyclin T (0.18 μM) and CK1δ/ε (0.4 μM). (R)-CR8 induces apoptosis and has neuroprotective effect . (R)-CR8 acts as a molecular glue degrader that depletes cyclin K .

HY-13914

Roniciclib 2 Publications Verification BAY 1000394	CDK	Cancer
Roniciclib is an orally bioavailable pan-cyclin dependent kinase *(CDK)* inhibitor, with IC₅₀s of 5-25 nM for CDK1, CDK2, CDK3, CDK4, CDK7 and CDK9.

HY-10424

Milciclib 5+ Cited Publications PHA-848125	CDK Autophagy	Cancer
Milciclib (PHA-848125) is a potent, ATP-competitive and dual inhibitor of *CDK* and Tropomyosin receptor kinase (TRK), with IC₅₀s of 45, 150, 160, 363, 398 nM and 53 nM for cyclin A/CDK2, cyclin H/CDK7, cyclin D1/CDK4, cyclin E/CDK2, cyclin B/CDK1 and TRKA, respectively.

HY-103712

Samuraciclib 10+ Cited Publications CT7001; ICEC0942	CDK Apoptosis	Cancer
Samuraciclib (CT7001) is a potent, selective, ATP-competitive and orally active *CDK7* inhibitor, with an IC₅₀ of 41 nM. Samuraciclib displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2 (IC₅₀ of 578 nM), CDK5 and CDK9, respectively. Samuraciclib inhibits the growth of breast cancer cell lines with GI₅₀ values between 0.2-0.3 μM. Samuraciclib has anti-tumor effects .

HY-161830

CDK7 ligand 2	Ligands for Target Protein for PROTAC CDK	Cancer
CDK7 ligand 2 (Compound A6) is a CDK7 ligand. CDK7 ligand 2 can be used in the synthesis of PROTACs .

HY-12280

THZ2 5 Publications Verification	CDK	Cancer
THZ2 is a potent and selective *CDK7* inhibitor with an IC₅₀ of 13.9 nM.

HY-12653

LDC4297 5+ Cited Publications	CDK HIV HSV	Infection
LDC4297 is a selective inhibitor of *CDK7* with an IC₅₀ value of 0.13 nM. LDC4297 inhibits human cytomegalovirus (HCMV) replication with an EC₅₀ value of 24.5 nM. LDC4297 shows broad antiviral activities to Herpesviridae, Adenoviridae, Poxviridae, Retroviridae and Orthomyxoviridae with EC₅₀ value of 0.02-1.21 μM. LDC4297 can be used for the research of infection .

HY-18285

Longdaysin	Wnt Casein Kinase ERK CDK	Cancer
Longdaysin is a inhibitor of the Wnt/β-catenin signaling pathway, which exerts antitumor effect through blocking CK1δ/ε-dependent Wnt signaling. Longdaysin inhibits CK1α, CK1δ, *CDK7, and ERK2* with IC₅₀s of 5.6 µM, 8.8 µM, 29 µM, and 52 µM, respectively .

HY-11009

CGP60474 5+ Cited Publications	CDK PKC	Cancer
CGP60474, a highly potent anti-endotoxemic agent, is a potent cyclin-dependent kinase (CDK) inhibitor (IC₅₀ values are 26, 3, 4, 216, 10, 200 and 13 nM for CDK1/B, CDK2/E, CDK2/A, CDK4/D, CDK5/p25, CDK7/H and CDK9/T, respectively). CGP60474 is a selective and ATP-competitive PKC inhibitor .

HY-13266A

BS-181 hydrochloride 5+ Cited Publications	CDK	Cancer
BS-181 hydrochloride is a highly selective *CDK7* inhibitor with IC₅₀ of 21 nM, and > 40-fold selective for CDK7 than CDK1, 2, 4, 5, 6, or 9.

HY-12293

LY2857785 4 Publications Verification	CDK Apoptosis	Cancer
LY2857785 is a type I reversible and competitive ATP kinase inhibitor against *CDK9* (IC₅₀ 11 nM) and other transcription kinases *CDK8* (IC₅₀ 16 nM), and *CDK7* (IC₅₀ 246 nM).

HY-80013A

THZ1 Hydrochloride Maximum Cited Publications 93 Publications Verification	CDK	Cancer
THZ1 Hydrochloride is a selective and potent covalent *CDK7* inhibitor with an IC₅₀ of 3.2 nM. THZ1 Hydrochloride also inhibits the closely related kinases *CDK12* and *CDK13* and downregulates MYC expression .

HY-162706

BSJ-5-63 1 Publications Verification	PROTACs CDK	Cancer
BSJ-5-63 is a potent *CDK12, CDK7, CDK9* PROTAC degrader. BSJ-5-63 BSJ-5-63 decreases the protein expression of CDK12, CDK7, CDK9, RNAPII, Cyclin K. BSJ-5-63 decreases the mRNA expression of BRCA1, BRCA2. BSJ-5-63 shows anticancer activity and has the potential for the research of prostate cancer (Pink: ligand for target protein (HY-150948); black: linker (HY-W140827); Blue: E3 ligase ligand (HY-112078)) .

HY-128587

Mevociclib 5+ Cited Publications SY-1365	CDK	Cancer
Mevociclib (SY-1365) is a potent and first-in-class selective *CDK7* inhibitor, with a K_i of 17.4 nM. Mevociclib exhibits anti-proliferative and apoptotic effects in solid tumor cell lines. Mevociclib possesses anti-tumor activity in hematological and multiple aggressive solid tumors .

HY-128867

bio-THZ1 1 Publications Verification	CDK	Cancer
bio-THZ1 is a biotinylated version of THZ1 and binds irreversibly to CDK7. THZ1 is a selective and potent covalent *CDK7* inhibitor with an IC₅₀ of 3.2 nM .

HY-19988

THZ1-R 3 Publications Verification	CDK	Cancer
THZ1-R is a non-cysteine reactive analog of THZ1 which displays diminished activity for *CDK7* inhibition. THZ1-R binds to *CDK7* with a K_d of 142 nM.

HY-139342

CDK7-IN-4	CDK	Cancer
CDK7-IN-4 (compound I) is a potent *CDK7* (Cyclin-dependent kinase 7) inhibitor. CDK7-IN-4 shows anticancer activity. CDK7-IN-4 inhibits the in vitro growth of cancer cell lines from a variety of histologies including colon , breast , lung , ovary and stomach , in a dose dependent manner .

HY-46568

CDK7/12-IN-1	CDK	Cancer
CDK7/12-IN-1 is a selective *CDK7/12* inhibitor with IC₅₀s of 3 and 277 nM for CDK7 and CDK 12, respectively. CDK7 and CDK12 inhibition is an effective strategy to inhibit tumour growth .

HY-161828

JWZ-5-13	PROTACs CDK	Cancer
JWZ-5-13 is a *CDK7* PROTAC degrader. JWZ-5-13 inhibits the proliferation of cancer cells. JWZ-5-13 is applicable to the research of ovarian cancer, diffuse large B-cell lymphoma, acute T-lymphoblastic leukemia and non-small cell lung cancer .

HY-117203A

CDK12-IN-E9 1 Publications Verification	CDK	Cancer
CDK12-IN-E9 is a potent and selective covalent *CDK12* inhibitor and a non-covalent *CDK9* inhibitor, while avoiding ABC transporter-mediated efflux. CDK12-IN-E9 has weak binding ability to CDK7/CyclinH complex with an IC₅₀> 1 μM .

HY-101257B

YKL-5-124 TFA 15+ Cited Publications	CDK	Cancer
YKL-5-124 TFA is a potent, selective, irreversible and covalent *CDK7* inhibitor with IC₅₀s of 53.5 nM and 9.7 nM for *CDK7* and *CDK7/Mat1/CycH, respectively. YKL-5-124 TFA is >100-fold greater selective for CDK7* than CDK9 and CDK2, and inactive against CDK12 and CDK13. YKL-5-124 TFA induces a strong cell-cycle arrest, inhibits E2F-driven gene expression, and exhibits little effect on RNA polymerase II phosphorylation status .

HY-18340A

(R)-CR8 trihydrochloride 1 Publications Verification CR8, (R)-Isomer trihydrochloride	Molecular Glues CDK Apoptosis	Neurological Disease Cancer
(R)-CR8 (CR8) trihydrochloride, a second-generation analog of Roscovitine, is a potent *CDK1/2/5/7/9* inhibitor. (R)-CR8 trihydrochloride inhibits CDK1/cyclin B (IC₅₀=0.09 μM), CDK2/cyclin A (0.072 μM), CDK2/cyclin E (0.041 μM), CDK5/p25 (0.11 μM), CDK7/cyclin H (1.1 μM), CDK9/cyclin T (0.18 μM) and CK1δ/ε (0.4 μM). (R)-CR8 trihydrochloride induces apoptosis and has neuroprotective effect . (R)-CR8 trihydrochloride acts as a molecular glue degrader that depletes cyclin K .

HY-147600

CDK7-IN-15	CDK	Cancer
CDK7-IN-15 (Compound 8) is a selective *CDK7* inhibitor with an IC₅₀ greater than 10 nM and less than or equal to 100 nM. CDK7-IN-15 is applicable to the research of cancers associated with transcriptional dysregulation .

HY-123955

Casein Kinase inhibitor A86	Casein Kinase CDK Apoptosis	Cancer
Casein Kinase inhibitor A86 is a potent and orally active casein kinase 1α (CK1α) inhibitor. Casein Kinase inhibitor A86 also inhibits of CDK7 (TFIIH) and CDK9 (P-TEFb). Casein Kinase inhibitor A861 induces leukemia cell apoptosis, and has potent anti-leukemic activities .

HY-103712C

Samuraciclib hydrochloride hydrate 10+ Cited Publications CT7001 hydrochloride hydrate; ICEC0942 hydrochloride hydrate	CDK Apoptosis	Cancer
Samuraciclib (CT7001) hydrochloride hydrate is a potent, selective, ATP-competitive and orally active *CDK7* inhibitor, with an IC₅₀ of 41 nM. Samuraciclib hydrochloride hydrate displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2 (IC₅₀ of 578 nM), CDK5 and CDK9, respectively. Samuraciclib hydrochloride hydrate inhibits the growth of breast cancer cell lines with GI₅₀ values between 0.2-0.3 μM. Samuraciclib hydrochloride hydrate has anti-tumor effects .

HY-103712B

Samuraciclib hydrochloride dihydrate 10+ Cited Publications CT7001 hydrochloride dihydrate; ICEC0942 hydrochloride dihydrate	CDK Apoptosis	Cancer
Samuraciclib (CT7001) hydrochloride hydrate is a potent, selective, ATP-competitive and orally active *CDK7* inhibitor, with an IC₅₀ of 41 nM. Samuraciclib hydrochloride hydrate displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2 (IC₅₀ of 578 nM), CDK5 and CDK9, respectively. Samuraciclib hydrochloride hydrate inhibits the growth of breast cancer cell lines with GI₅₀ values between 0.2-0.3 μM. Samuraciclib hydrochloride hydrate has anti-tumor effects .

HY-161829

CDK7 ligand 1	Ligands for Target Protein for PROTAC	Cancer
CDK7 ligand 1 is an active control ligand for CDK7 ligand 2 (HY-161830). CDK7 ligand 2 is a CDK7 ligand. CDK7 ligand 2 can be used in the synthesis of PROTACs .

HY-161828A

(S)-JWZ-5-13	PROTACs CDK	Cancer
(S)-JWZ-5-13 (compound 17-Neg), a PROTAC CDK7 degrader, is a negative control compound of JWZ-5-13 (HY-161828). (S)-JWZ-5-13 displays similar in vitro CDK7 inhibition (IC₅₀ = 21.1 nM) to JWZ-5-13, but fails to induce CDK7 degradation in cells .

HY-12653A

LDC4297 hydrochloride 5+ Cited Publications	CDK HIV HSV	Infection
LDC4297 hydrochloride is a selective inhibitor of *CDK7* with an IC₅₀ value of 0.13 nM. LDC4297 hydrochloride inhibits human cytomegalovirus (HCMV) replication with an EC₅₀ value of 24.5 nM. LDC4297 hydrochloride shows broad antiviral activities to Herpesviridae, Adenoviridae, Poxviridae, Retroviridae and Orthomyxoviridae with EC₅₀ values of 0.02-1.21 μM. LDC4297 hydrochloride can be used for the research of infection .

HY-14372

BS-194	CDK	Cancer
BS-194 is an orally active, selective and potent *CDK* inhibitor. BS-194 inhibits CDK2, CDK1, CDK5, CDK7, CDK9 (IC₅₀s: 3, 30, 30, 250, and 90 nM respectively). BS-194 potently inhibits cancer cells proliferation. BS-194 can be used in the research of cancers like breast cancer, colon cancer .

HY-155218

TMX-2172	PROTACs CDK	Cancer
TMX-2172 is a selective bivalent cereblon-recruiting PROTAC-based dual *CDK2* and *CDK5* degrader with IC₅₀ values of 6.5 nM and 6.8 nM, respectively. TMX-2172 shows selectivity for CDK2 and CDK5 over other cell cycle CDKs (CDK1, CDK4, and CDK6) and transcriptional CDKs (CDK7 and CDK9). TMX-2172 inhibits CDK2/CDK5 enzymatic activity, induces their proteasomal degradation, reduces ASCL1 protein levels and half-life, induces cancer cell death, and exerts antiproliferative effects. TMX-2172 can be used for the research of ovarian cancer and small cell lung cancer .

HY-147597

CDK7-IN-13	CDK	Cancer
CDK7-IN-13 is a potent inhibitor of *CDK7. CDK7-IN-13* is a pyrimidinyl derivative compound. CDK7-IN-13 has the potential for the research of various cancers, especially the cancer with transcriptional dysregulation (extracted from patent CN114249712A, compound 1) .

HY-116871

YKL-1-116	CDK	Cancer
YKL-1-116 is a selective and covalent inhibitor of *Cdk7. YKL-1-116 does not target Cdk9, Cdk12, or Cdk13. YKL-1-116 is more potent than THZ1 (HY-80013) toward both Cdk7* ^WT and Cdk7 ^as, although Cdk7 ^as is relatively resistant to this compound as well .

HY-155787

SHR5428	CDK	Cancer
SHR5428 is a potent, orally active, selective and noncovalent inhibitor of *CDK7* with highly potent CDK7 enzymatic activity (IC₅₀=2.3 nM). SHR5428 inhibits triple negative breast cancer cellular activity on MDA-MB-468 cell (IC₅₀=6.6 nM) .

HY-158170

CDK7-IN-28	CDK	Cancer
CDK7-IN-28 (CDK7-1276) is a potent *CDK7* inhibitor(IC₅₀＜5 nM). CDK7-IN-28 can inhibit proliferation of MDA-MB-468 cell line by blocking cell cycle and inhibiting DNA replication .

HY-163856

CDK7-IN-30	Apoptosis DNA/RNA Synthesis CDK	Cancer
CDK7-IN-30 (Compound 22) is a *CDK7* inhibitor (IC₅₀ = 7.21 nM) that effectively inhibits the phosphorylation of RNA Polymerase II and *CDK2. CDK7-IN-30* CDK7-IN-30 can induce cell apoptosis and has anti-cancer activity and can be used in cancer research .

HY-P2559

CDK7/9 tide	CDK	Cancer
CDK7/9 tide is peptide substrate for CDK7 or CDK9 .

HY-151069

TMX-2039	Ligands for Target Protein for PROTAC CDK	Cancer
TMX-2039 is a *pan-CDK* inhibitor for both cell cycle *CDKs (CDK1,* *CDK2, CDK4, CDK5* and *CDK6) and transcriptional CDKs (CDK7* and *CDK9), with IC₅₀s of 2.6, 1.0, 52.1, 0.5, 35.0, 32.5 and 25 nM, respectively. TMX-2039 acts as a Ligands for Target Protein* for PROTACs .

HY-18969

LDC3140	CDK	Cancer
LDC3140 is a selective CDK7 inhibitor (IC₅₀<5 nM). By inhibiting the activity of CDK7, LDC3140 affects the regulation of the cell cycle, leading to cell cycle arrest and thus inhibiting the proliferation of tumor cells. LDC3140 can be used in the research of cancer treatment .

HY-145655

CDK7-IN-11	CDK	Cancer
CDK7-IN-11 is an orally active *CDK7* inhibitor. CDK7-IN-11 exhibits high CDK7 inhibitory activity with IC₅₀ value of 4.2 nM. CDK7-IN-11 can be effectively used for the research of diseases associated with CDK7 .

HY-147598

CDK7-IN-14	CDK	Cancer
CDK7-IN-14 is a potent inhibitor of *CDK7. CDK7-IN-14* is a pyrimidinyl derivative compound. CDK7-IN-14 has the potential for the research of various cancers, especially the cancer with transcriptional dysregulation (extracted from patent CN114249712A, compound 3) .

HY-151878

CDK7-IN-20	CDK GSK-3	Metabolic Disease
CDK7-IN-20 is a potent, selective and irreversible *CDK7* (CDK) inhibitor with an IC₅₀ value of 4 nM. CDK7-IN-20 displays >206-fold selectivity for CDK7 over CDK1, CDK2, CDK3, CDK5, CDK6, CDK9 and CDK12 . CDK7-IN-20 has the potential for autosomal dominant polycystic kidney disease (ADPKD) research .

HY-163721

CDK7-IN-29	CDK	Cancer
CDK7-IN-29 (compound 20) is an inhibitor of CDK7 with an IC₅₀ value of 1.4 nM. CDK7-IN-29 has oral activity and good pharmacokinetic (PK) properties .

HY-13266

BS-181	CDK Apoptosis	Cancer
BS-181 is a potent and selective *CDK7* inhibitor (IC₅₀=21 nM) than Seliciclib (HY-30237). BS-181 is also against CDK2, CDK5 and CDK9 with IC₅₀ values of 880, 3000 and 4200 nM, respectively (fails to block CDK1, 4 and 6). BS-181 inhibits a panel of cancer cells growth (IC₅₀=11.5 μM-37.3 μM) and induces cell apoptosis. BS-181 has the potential for the research of cancer therapy .

Cat. No.	Product Name	Target	Research Area

HY-P2559

CDK7/9 tide	CDK	Cancer
CDK7/9 tide is peptide substrate for CDK7 or CDK9 .

HY-P1933

[pSer2, pSer5, pSer7]-CTD	Peptides	Cancer
[pSer2, pSer5, pSer7]-CTD, a substrate for CDK7 (cyclin dependent protein kinase), is a phosphorylated polypeptide at ser2, ser5 and ser7 sites of RNA polymerase II carboxy-terminal domain (CTD) .

HY-P1933A

[pSer2, pSer5, pSer7]-CTD TFA	CDK	Cancer
[pSer2, pSer5, pSer7]-CTD (TFA), a substrate for CDK7 (cyclin dependent protein kinase), is a phosphorylated polypeptide at ser2, ser5 and ser7 sites of RNA polymerase II carboxy-terminal domain (CTD) .

Recombinant Proteins Recommended:

Cyclin-Dependent Kinase 7 (CDK7)

Species:	Human (4)
Tag:	His (2) Tag Free (1) GST (2) Flag (1)
Source:	Sf9 insect cells (4)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P703556

	CDK7 Protein, Human (sf9, GST) CAK; CAK1; cdkN7; MO15; STK1	Human	Sf9 insect cells
	Together with its regulatory partners CCNH and MNAT1, CDK7 functions as an important serine/threonine kinase in cell cycle regulation and RNA polymerase II-mediated transcription. As the catalytic subunit of the CDK-activated kinase (CAK) complex, CDK7 plays a key role in activating CDK1/cyclin-B and CDK2/cyclin during cell cycle transitions. CDK7 Protein, Human (Sf9, GST) is the recombinant human-derived CDK7, expressed by Sf9 insect cells, with GST labeled tag. The total length of CDK7 Protein, Human (Sf9, GST) is 346 a.a..

HY-P701371

	CDK7-CCNH-MNAT1 Protein, Human (sf9) cdk7; CCNH; MNAT1; Cyclin-dependent kinase 7; 39 kDa protein kinase; p39 Mo15; cdk-activating kinase 1; Cell division protein kinase 7; Serine/threonine-protein kinase 1; TFIIH basal transcription factor complex kinase subunit; Cyclin-H; MO15-associated protein; p34; p37; cdk-activating kinase assembly factor MAT1; cdk7/cyclin-H assembly factor; Cyclin-G1-interacting protein; Menage a trois; RING finger protein 66; RING finger protein MAT1; p35; p36	Human	Sf9 insect cells
	Together with its regulatory partners CCNH and MNAT1, CDK7 functions as an important serine/threonine kinase in cell cycle regulation and RNA polymerase II-mediated transcription. As the catalytic subunit of the CDK-activated kinase (CAK) complex, CDK7 plays a key role in activating CDK1/cyclin-B and CDK2/cyclin during cell cycle transitions. CDK7-CCNH-MNAT1 Protein, Human (sf9) is the recombinant human-derived CDK7-CCNH-MNAT1 protein, expressed by sf9 insect cells , with tag free.

HY-P702688

	CDK7-CCNH-MNAT1 Protein, Human (Active, sf9, GST, His, Flag) cdk7; cyclin-dependent kinase 7; cyclin dependent kinase 7 (homolog of Xenopus MO15 cdk activating kinase) , cyclin dependent kinase 7 (MO15 homolog, Xenopus laevis, cdk activating kinase); CAK; CAK1; cdkN7; MO15; STK1; p39 Mo15; protein kinase; 39 KDa protein kinase; kinase subunit of CAK; cdk-activating kinase 1; serine/threonine kinase stk1; cell division protein kinase 7; serine/threonine protein kinase 1; serine/threonine-protein kinase 1; serine/threonine protein kinase MO15	Human	Sf9 insect cells
	Together with its regulatory partners CCNH and MNAT1, CDK7 functions as an important serine/threonine kinase in cell cycle regulation and RNA polymerase II-mediated transcription. As the catalytic subunit of the CDK-activated kinase (CAK) complex, CDK7 plays a key role in activating CDK1/cyclin-B and CDK2/cyclin during cell cycle transitions. CDK7-CCNH-MNAT1 Protein, Human (sf9, GST, His, Flag) is the recombinant human-derived CDK7-CCNH-MNAT1, expressed by Sf9 insect cells, with N-His, N-GST, N-Flag labeled tag.

HY-P75361

	CDK7-CCNH-MNAT1 Protein, Human (Active, sf9, His) CAK1 Protein; cdkN7 Protein; HCAK Protein; MO15 Protein; p39MO15 Protein; STK1 Protein	Human	Sf9 insect cells
	Together with its regulatory partners CCNH and MNAT1, CDK7 functions as an important serine/threonine kinase in cell cycle regulation and RNA polymerase II-mediated transcription. As the catalytic subunit of the CDK-activated kinase (CAK) complex, CDK7 plays a key role in activating CDK1/cyclin-B and CDK2/cyclin during cell cycle transitions. CDK7-CCNH-MNAT1 Protein, Human (sf9, His) is the recombinant human-derived CDK7-CCNH-MNAT1 protein, expressed by Sf9 insect cells , with N-His labeled tag. CDK7-CCNH-MNAT1 Protein, Human (sf9, His), has molecular weight of ~25 & 38 & 44 kDa, respectively.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P80389

	Cdk7 Antibody (YA3495) cdk7_HUMAN; Cyclin-dependent kinase 7; EC:2.7.11.22; EC:2.7.11.23; cdk7; CAK; CAK1; cdkN7; MO15; STK1; 39 kDa protein kinase (p39 Mo15); cdk-activating kinase 1; Cell division protein kinase 7; Serine/threonine-protein kinase 1; TFIIH basal transcription factor complex kinase subunit;	WB	Human
	Cdk7 Antibody (YA3495) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Cdk7.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: